Benchmark raises Exact Sciences stock price target to $60 on cancer test launch
PositiveFinancial Markets

Benchmark has raised its price target for Exact Sciences to $60 following the launch of a new cancer test. This is significant as it reflects confidence in the company's innovative approach to cancer diagnostics, which could lead to improved patient outcomes and potentially boost the company's market position.
— Curated by the World Pulse Now AI Editorial System